PNV - Banter and General Comments, page-6952

Yes that definitely seems the case, thus the importance of getting approval to market and sell the BTM product in a range of different sizes, thicknesses to diversify use and move away from the initial game-changing burns applications and get approval for wound dressings across a range of clinical presentations.

I would also hope and like to see some updates on the breast slings if possible, and the hernia product (although this is already a crowded house so to speak). Overall, the need for diversity at this stage of the development from a spec stock to an ASX200 stock I think is vital for increased sales and thus profit, and until then we rely on intermittent announcements following which the SP reacts either very well or modestly depending on how that announcement is viewed. When we have strong monthly sales over a sustained period, those announcements may have less of an impact as the SP should already be strong in terms of value on the back of consistent numbers, as always stay well and DYOR!